Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-SC01 for Complex Perianal Fistulas in Crohn's Disease
NCT04939337Phase 1Unknown
- Sponsor
- Jinling Hospital
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TH-SC01 in Crohn's disease, sponsored by Jinling Hospital. Primary endpoints: Combined Remission at 24 weeks and Safety at 24 weeks. Status: unknown.
02
Drugs
TH-SC01
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04939337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939337.